Building on proven cardiometabolic outcomes, 9amHealth combines specialty care and lower-cost medication access to help employers manage complex chronic conditions and rising pharmacy costs.

SAN DIEGO, Nov. 10, 2026 /PRNewswire/ — 9amHealth, a leading specialty care platform, today announced its expansion into autoimmune care and the introduction of 9amRx Direct, a medication access offering outside the traditional pharmacy model. Together, they give employers a more integrated way to manage complex chronic conditions and high-cost medications.

In 2025, specialty medications accounted for more than 53% of U.S. prescription medication expenditures, with inflammatory and autoimmune conditions representing approximately one-third of overall spending. Biologic therapies for these conditions can cost between $21,000 and $47,000 per patient annually, with some medications costing more than $21,000 per treatment. As costs rise, employers need solutions that address both the clinical complexity of these conditions and the medications used to treat them. 

9amHealth’s new autoimmune program builds on its established cardiometabolic care model to support people living with rheumatoid arthritis, psoriatic arthritis, and other inflammatory autoimmune conditions. Its multidisciplinary Care Team provides ongoing support for pain, fatigue, and flares, while pharmacists help manage medication use, biologic therapies, and biosimilar transitions when clinically appropriate. 

“Inflammatory autoimmune conditions and cardiometabolic conditions share many similarities; treatment is complex, access to care is fragmented, and utilization of high-cost medications has risen dramatically in the past 10 years,” said Paul Geevarghese, PharmD, Co-CEO of 9amHealth. “We’re bringing care, medication and cost management together so employers have one place to rely on for better outcomes while spending less.”

Complementing its care clinics, 9amHealth now offers 9amRx Direct, giving employers access to high-cost medications outside the pharmacy benefit. The offering combines medication access at 30-50% below average industry pricing with claims administration and billing. Already available for GLP-1 weight-loss medications, it will expand to autoimmune specialty medications in 2027. Based on internal economic modeling, 9amRx Direct could deliver up to 4x return on investment in the first year.

Together, 9amHealth’s specialty clinics and medication access offerings give employers a more coordinated approach to managing specialty care and costs while improving outcomes.

To learn more, visit 9am.health or connect with the 9amHealth team at HLTH in Las Vegas, meeting pod MP-6658.

9amHealth is a specialty chronic care platform that helps members achieve better health outcomes while reducing healthcare costs for employers and health plans. Its cardiometabolic and autoimmune clinics bring together specialized care teams to provide personalized, coordinated treatment for conditions including obesity, diabetes, hypertension, high cholesterol, rheumatoid arthritis, and psoriatic arthritis. Supported by technology, the platform simplifies access to specialists, prescriptions, labs, and ongoing lifestyle support. Through 9amRx Direct, 9amHealth also helps employers manage spending on high-cost medications by providing more direct, transparent access to lower-cost alternatives.

9amHealth was founded in 2021 and is backed by leading healthcare investors, including Define Ventures, 7wire Ventures, and The Cigna Group Ventures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/9amhealth-expands-into-autoimmune-care-and-introduces-9amrx-direct-to-lower-high-cost-medication-spend-302934123.html

SOURCE 9amHealth